Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …

Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for
harnessing the potential of a patient's own immune system to eliminate tumor cells in …

The immunosuppressive tumor microenvironment (TME) represents a major barrier for
effective immunotherapy. Tumor-associated macrophages (TAMs) are highly heterogeneous …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

We conducted a pilot clinical trial testing a personalized vaccine generated by autologous
dendritic cells (DCs) pulsed with oxidized autologous whole-tumor cell lysate (OCDC) …

T-lymphocytes play a critical role in cancer immunity as evidenced by their presence in
resected tumor samples derived from long-surviving patients, and impressive clinical …

Tumor vaccination is a promising approach for tumor immunotherapy because it presents
high specificity and few side effects. However, tumor vaccines that contain only a single …

The accumulation of tumor infiltrating lymphocytes (TILs) in ovarian cancer is prognostic for
increased survival while increases in immunosuppressive regulatory T-cells (Tregs) are …

Dendritic cells (DCs) are essential in immunity owing to their role in activating T cells,
thereby promoting antitumor responses. Tumor cells, however, hijack the immune system …

Increasing evidence indicates CD4+ T cells can recognize cancer-specific antigens and
control tumor growth. However, it remains difficult to predict the antigens that will be …